This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

The Effect of Prescription Medications in Marijuana Users

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified May 2009 by Johns Hopkins University.
Recruitment status was:  Recruiting
National Institute on Drug Abuse (NIDA)
Information provided by:
Johns Hopkins University Identifier:
First received: April 30, 2009
Last updated: July 15, 2011
Last verified: May 2009
A subset of heavy marijuana users have trouble quitting marijuana use and the number of those seeking treatment for problems related to marijuana is increasing. The purpose of this research study is to investigate whether certain medications can reduce withdrawal effects associated with stopping marijuana use, if they can reduce the rewarding effects of smoked marijuana, and whether there are any cognitive performance deficits associated with the medications that produce such effects.

Condition Intervention Phase
Marijuana Abuse Drug: bupropion, diazepam, dronabinol, ramelteon (Investigational Drug) Phase 1 Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Crossover Assignment
Masking: Double Blind (Participant, Outcomes Assessor)
Primary Purpose: Basic Science
Official Title: The Effect of Prescription Medications in Marijuana Users

Resource links provided by NLM:

Further study details as provided by Johns Hopkins University:

Primary Outcome Measures:
  • marijuana withdrawal [ Time Frame: Every day during study participation ]
  • subjective effects of smoked marijuana [ Time Frame: Every 5-9 days ]

Secondary Outcome Measures:
  • cognitive performance [ Time Frame: Every 5-9 days ]

Estimated Enrollment: 21
Study Start Date: April 2009
Estimated Study Completion Date: October 2011
Estimated Primary Completion Date: October 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
No Intervention: Marijuana Use
Period during which participants are free to self administer marijuana
Experimental: Marijuana Abstinence
Period during which marijuana use is prohibited and study medication is administered
Drug: bupropion, diazepam, dronabinol, ramelteon (Investigational Drug)
multiple doses of an investigational drug administered three times per day, double blind during brief periods of marijuana abstinence
Other Names:
  • buproprion
  • diazepam
  • dronabinol
  • ramelteon


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • current use of marijuana
  • able to give informed consent

Exclusion Criteria:

  • dependence on drug other than marijuana
  • pregnant, breast feeding, or planning to become pregnant within the next 3 months
  • currently seeking treatment for cannabis-related problems or otherwise trying to reduce use
  • use of cannabis under the guidance of a physician for a medical disorder
  • unstable or uncontrolled cardiovascular disease (e.g., hypertension, angina)
  • allergy to study medication
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00893074

Contact: Sarah Ilk 410-550-0007

United States, Maryland
Behavioral Pharmacology Research Unit Recruiting
Baltimore, Maryland, United States, 21224
Contact: Sarah Ilk    410-550-0007      
Principal Investigator: Ryan Vandrey, Ph.D.         
Sponsors and Collaborators
Johns Hopkins University
National Institute on Drug Abuse (NIDA)
Principal Investigator: Ryan Vandrey, Ph.D. Johns Hopkins University
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Ryan Vandrey, Ph.D., Johns Hopkins University School of Medicine Identifier: NCT00893074     History of Changes
Other Study ID Numbers: NA_00026278
R01DA025044 ( U.S. NIH Grant/Contract )
Study First Received: April 30, 2009
Last Updated: July 15, 2011

Keywords provided by Johns Hopkins University:
acute effects
cognitive performance
Marijuana Use
Marijuana Abstinence

Additional relevant MeSH terms:
Marijuana Abuse
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Antidepressive Agents, Second-Generation
Antidepressive Agents
Psychotropic Drugs
Dopamine Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Dopamine Agents
Neurotransmitter Agents
Physiological Effects of Drugs
Cytochrome P-450 CYP2D6 Inhibitors
Cytochrome P-450 Enzyme Inhibitors
Enzyme Inhibitors
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Cannabinoid Receptor Agonists
Cannabinoid Receptor Modulators
Hormones, Hormone Substitutes, and Hormone Antagonists
Adjuvants, Anesthesia processed this record on July 26, 2017